Brought to you by 
Amgen to Acquire Teneobio For a Total Consideration of $2.5B; Closes Acquisition
26 Oct 2021
Executive Summary
Amgen, Inc. entered into an agreement to acquire Teneobio, Inc., a privately held clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies for a total consideration of $2.5B. The acquisition is expected to close in Q3 or Q4 2021.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen to Acquire Teneobio For a Total Consideration of $2.5B; Closes Acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice